As a result of the advances in antibody discovery technologies in hybridoma, display libraries, Single B-cell sorting/sequencing and computational modeling, thousands of mAbs have been generated in antibody discovery campaigns. To rapidly find “best-in-class” antibody therapeutics, it has become essential to develop high throughput (HTP) processes that allow rapid assessment of antibodies for functional and molecular properties.
BioIntron has developed a high throughput (HTP) platform to offer our customers the flexibility to rapidly express a large number of antibodies at various scale in HEK293/CHO cell.
